Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AstraZeneca
Cholesterol-lowering Crestor granted FDA approval
September 10th, 2003
AstraZeneca (AZN) announced that its new cholesterol-lowering medication, Crestor (rosuvastatin calcium) has received approval from the U.S. Food and Drug Administration (FDA) as an adjunct to diet for the treatment of various lipid disorders, including primary hypercholesterolemia, mixed dyslipidemia, and isolated hypertriglyceridemia. Crestor is the newest member of the cholesterol-lowering statin (HMG-CoA reductase inhibitors) class of drug therapy. In a 6-week dose-ranging placebo-controlled study using a 5, 10, 20, or 40 mg dose, Crestor lowered LDL-cholesterol by 45 to 63% (7% for placebo), and increased HDL- cholesterol by 8 to 14% (3% for placebo). ...
Source: Biotech Week (2003-09-10)
|
